Will better neurotech regulations be enough to address privacy, effectiveness and potential harm concerns?

See above the fas­ci­nat­ing pre­sen­ta­tions by Dr. Anna Wexler, Dr. Karen Rom­melfanger and Jacque­line Stud­er on pri­va­cy and ethics dur­ing the 2019 Sharp­Brains Vir­tu­al Sum­mit.

We still lack clear stan­dards and tax­onomies for neu­rotech­nol­o­gy but sev­er­al ini­tia­tives are under­way to antic­i­pate and address the chal­lenges. One impor­tant take-away is that it is impor­tant to be aspi­ra­tional and prag­mat­ic rather than “legal­is­tic” — by con­sid­er­ing diverse pol­i­cy and indus­try per­spec­tives, striv­ing for the widest ben­e­fit with the min­i­mum risks, and bet­ter edu­cat­ing users, we can enable ben­e­fi­cial inno­va­tion in ways that reg­u­la­tion alone –as impor­tant as it is– cannot.

News in Context:

About SharpBrains

SHARPBRAINS is an independent think-tank and consulting firm providing services at the frontier of applied neuroscience, health, leadership and innovation.
SHARPBRAINS es un think-tank y consultoría independiente proporcionando servicios para la neurociencia aplicada, salud, liderazgo e innovación.

Top Articles on Brain Health and Neuroplasticity

Top 10 Brain Teasers and Illusions


Subscribe to our e-newsletter

* indicates required

Got the book?